CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology)

N/A

Report date: 2024/12/19 10:55:05

Base Information

Drug NameCD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology)
Drug Alias NameLCAR-HL30 cells therapy(Legend Biotechnology)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCell replacementsTumor necrosis factor receptor superfamily member 8 modulators
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, Large-Cell, AnaplasticHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Legend Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Large-Cell, AnaplasticHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A